SGIM19105, Linehan, 4142-17, pancreatic and colorectal cancer, VX15/2503, ipilimumab,
How well does a monoclonal antibody, "anti-SEMA4D monoclonal antibody VX15/2503,"
work in treating patients with stage I-III pancreatic cancer?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This randomized phase I trial studies how well anti-semaphorin 4D (anti-SEMA4D) monoclonal
antibody VX15/2503 with or without ipilimumab or nivolumab work in treating patients
with stage I-III pancreatic cancer that can be removed by surgery or stage IV colorectal
cancer that has spread to the liver and can be removed by surgery. Monoclonal antibodies,
such as anti-SEMA4D monoclonal antibody VX15/2503, ipilimumab, and nivolumab, may
interfere with the ability of tumor cells to grow and spread.
Study Reference #: SGIM19105
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amber Johnson
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search